{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/combined-advanced-therapy-medicinal-products-european-regulatory-requirements-pathways-and#webpage",
"url": "https://www.fortrea.com/insights/combined-advanced-therapy-medicinal-products-european-regulatory-requirements-pathways-and",
"name": "Combined advanced therapy medicinal products: European regulatory requirements, pathways and processes",
"description": "This Fortrea white paper explores combined advanced therapy medicinal products and the EU pathways affecting advanced therapy development within European markets. The content focuses on combined advanced therapy medicinal products, ATMP classification, EU pathway considerations, and development requirements associated with combined ATMP programs. The white paper highlights considerations related to ATMP categorization, medical device integration, European compliance expectations, and pathway planning affecting combined advanced therapy medicinal products. Fortrea discusses perspectives designed to support understanding of EU pathways, strengthen combined ATMP classification planning, and address development considerations associated with advanced therapy medicinal products within the European Union. By integrating ATMP classification understanding with EU pathway planning and development considerations, the white paper provides insights into combined advanced therapy medicinal products and evolving European frameworks affecting advanced therapy development programs."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Combined advanced therapy medicinal products: European regulatory requirements, pathways and processes",
"item": "https://www.fortrea.com/insights/combined-advanced-therapy-medicinal-products-european-regulatory-requirements-pathways-and"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/combined-advanced-therapy-medicinal-products-european-regulatory-requirements-pathways-and#whitepaper",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/combined-advanced-therapy-medicinal-products-european-regulatory-requirements-pathways-and#webpage"
},
"headline": "Navigating EU Regulatory Pathways for Combined Advanced Therapy Medicinal Products | Fortrea White Paper",
"description": "This Fortrea white paper explores combined advanced therapy medicinal products and the EU pathways affecting advanced therapy development within European markets. The content focuses on combined advanced therapy medicinal products, ATMP classification, EU pathway considerations, and development requirements associated with combined ATMP programs. The white paper highlights considerations related to ATMP categorization, medical device integration, European compliance expectations, and pathway planning affecting combined advanced therapy medicinal products. Fortrea discusses perspectives designed to support understanding of EU pathways, strengthen combined ATMP classification planning, and address development considerations associated with advanced therapy medicinal products within the European Union. By integrating ATMP classification understanding with EU pathway planning and development considerations, the white paper provides insights into combined advanced therapy medicinal products and evolving European frameworks affecting advanced therapy development programs.",
"genre": "White Paper",
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2025-11-26",
"dateModified": "2025-11-26",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2025-11/catmps-eu-regulatory-pathways.pdf",
"encodingFormat": "application/pdf"
}
}
]
}